| Diagnosis | p | ||
---|---|---|---|---|
 | GHD | NSD | inactGH |  |
n | 36 | 23 | 16 | Â |
Before rhGH administration | ||||
age [years] | 12.0 ± 2.4 | 12.0 ± 2.9 | 12.9 ± 1.4 | 0.56 |
height SDS | -2.59 ± 0.53 | -2.91 ± 0.68 | -2.68 ± 0.49 | 0.57 |
TSH [mU/l] | 2.42 ± 0.91 | 2.18 ± 1.02 | 2,63 ± 0.94 | 0.69 |
FT4 [ng/dl] | 1.31 ± 0.13 | 1.28 ± 0.17 | 1.29 ± 0.15 | 0.45 |
IGF-I SDS | -1.77 ± 0.92 | -2.18 ± 1.23 | -2.36 ± 1.06 | 0.58 |
IGF-I/IGFBP-3 | 0.21 ± 0.08 | 0.16 ± 0.05 | 0.16 ± 0.05 | 0.31 |
After 3-6 months of rhGH therapy | ||||
TSH [mU/l] | 2.80 ± 1.28 | 2.60 ± 1.20 | 2.56 ± 1.60 | 0.77 |
FT4 [ng/dl] | 1.13 ± 0.17 | 1.13 ± 0.19 | 1.13 ± 0.13 | 0.73 |
IGF-I SDS | 0.33 ± 0.99 | 0.40 ± 0.89 | 0.33 ± 0.74 | 0.38 |
IGF-I/IGFBP-3 | 0.38 ± 0.13 | 0.37 ± 0.11 | 0.38 ± 0.11 | 0.86 |
After 1 year of rhGH therapy | ||||
TSH [mU/l] | 2.51 ± 1.23 | 2.15 ± 0.74 | 1.56 ± 0.45 | 0.005 |
FT4 [ng/dl] | 1.29 ± 0.18 | 1.27 ± 0.18 | 1.27 ± 0.13 | 0.72 |
IGF-I SDS | 0.78 ± 0.88 | 0.62 ± 0.69 | 0.45 ± 0.83 | 0.72 |
IGF-I/IGFBP-3 | 0.43 ± 0.12 | 0.41 ± 0.11 | 0.39 ± 0.09 | 0.86 |